FDA approves Blenrep for relapsed or refractory multiple myeloma

Published Date: 31 Oct 2025

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

2.

Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.

3.

AI catches one-third of interval breast cancers missed at screening

4.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

5.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot